Troy Wilson, JD, PhD

1990 Hertz Fellow
Find me on LinkedIn

Troy Wilson is a successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and, most importantly, patients.

Troy is one of Kura Oncology’s co-founders and has served as their President and Chief Executive Officer and as the chairman of our Board of Directors since their inception in August 2014. Previously, Dr. Wilson served as President and Chief Executive Officer of Wellspring Biosciences, Inc., a privately-held biopharmaceutical company, and its parent company Araxes Pharma LLC from July 2012 to March 2019 and as President and Chief Executive Officer of Avidity Biosciences LLC, a privately-held biopharmaceutical company, from November 2012 to February 2019. Dr. Wilson served as the President and Chief Executive Officer and a member of the Board of Directors of Intellikine, Inc., a privately-held biopharmaceutical company, from April 2007 to January 2012 and from August 2007 to January 2012, respectively, until its acquisition by Takeda Pharmaceutical Company Limited. He has also been a member of the board of directors of Puma Biotechnology, Inc., a publicly-held biopharmaceutical company, since October 2013, Executive Chairman and a member of the board of directors of Avidity Biosciences, Inc. since February 2019 and November 2012, respectively, Executive Chairman and a member of the board of directors of Wellspring Biosciences since February 2019 and July 2012, respectively, and a member of the board of managers of Araxes Pharma LLC since July 2012. Dr. Wilson holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from the University of California, Berkeley.

Graduate Studies

University of California, Berkeley
Chemistry
1) Development of an Oligosulfone Biopolymer
2) Progress Toward Coupled Quantum Dots

Undergraduate Studies

University of California, Berkeley